Migraine – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Migraine – Pipeline Review, H2 2017’, provides an overview of the Migraine pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Migraine

The report reviews pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Migraine therapeutics and enlists all their major and minor projects

The report assesses Migraine therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Migraine

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Migraine

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

Achelios Therapeutics Inc

Acorda Therapeutics Inc

Alder Biopharmaceuticals Inc

Allergan Plc

Amgen Inc

Aralez Pharmaceuticals Inc

Astellas Pharma Inc

Avanir Pharmaceuticals Inc

Biofrontera AG

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Charleston Laboratories Inc

Corium International Inc

Crossject SA

Eli Lilly and Co

Impel NeuroPharma Inc

InKemia IUCT Group SA

InStar Technologies AS

Insys Therapeutics Inc

IntelGenx Corp

Ionis Pharmaceuticals Inc

Klaria Pharma Holding AB

Monosol Rx LLC

NAL Pharmaceuticals Ltd

Pharmaleads SA

Promius Pharma LLC

Q BioMed Inc

Revance Therapeutics Inc

Shin Nippon Biomedical Laboratories Ltd

Suda Ltd

Teva Pharmaceutical Industries Ltd

TheraJect Inc

Tonix Pharmaceuticals Holding Corp

Trevena Inc

Trigemina Inc

TrioxBio Inc

Vertex Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Zosano Pharma Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Migraine - Overview 6

Migraine - Therapeutics Development 7

Migraine - Therapeutics Assessment 18

Migraine - Companies Involved in Therapeutics Development 28

Migraine - Drug Profiles 46

Migraine - Dormant Projects 171

Migraine - Discontinued Products 176

Migraine - Product Development Milestones 177

Appendix 192

List of Tables

List of Tables

Number of Products under Development for Migraine, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Migraine – Pipeline by 4P Therapeutics LLC, H2 2017

Migraine – Pipeline by Achelios Therapeutics Inc, H2 2017

Migraine – Pipeline by Acorda Therapeutics Inc, H2 2017

Migraine – Pipeline by Alder Biopharmaceuticals Inc, H2 2017

Migraine – Pipeline by Allergan Plc, H2 2017

Migraine – Pipeline by Amgen Inc, H2 2017

Migraine – Pipeline by Aralez Pharmaceuticals Inc, H2 2017

Migraine – Pipeline by Astellas Pharma Inc, H2 2017

Migraine – Pipeline by Avanir Pharmaceuticals Inc, H2 2017

Migraine – Pipeline by Biofrontera AG, H2 2017

Migraine – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017

Migraine – Pipeline by BioHealthonomics Inc, H2 2017

Migraine – Pipeline by Charleston Laboratories Inc, H2 2017

Migraine – Pipeline by Corium International Inc, H2 2017

Migraine – Pipeline by Crossject SA, H2 2017

Migraine – Pipeline by Eli Lilly and Co, H2 2017

Migraine – Pipeline by Impel NeuroPharma Inc, H2 2017

Migraine – Pipeline by InKemia IUCT Group SA, H2 2017

Migraine – Pipeline by InStar Technologies AS, H2 2017

Migraine – Pipeline by Insys Therapeutics Inc, H2 2017

Migraine – Pipeline by IntelGenx Corp, H2 2017

Migraine – Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Migraine – Pipeline by Klaria Pharma Holding AB, H2 2017

Migraine – Pipeline by Monosol Rx LLC, H2 2017

Migraine – Pipeline by NAL Pharmaceuticals Ltd, H2 2017

Migraine – Pipeline by Pharmaleads SA, H2 2017

Migraine – Pipeline by Promius Pharma LLC, H2 2017

Migraine – Pipeline by Q BioMed Inc, H2 2017

Migraine – Pipeline by Revance Therapeutics Inc, H2 2017

Migraine – Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2017

Migraine – Pipeline by Suda Ltd, H2 2017

Migraine – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Migraine – Pipeline by TheraJect Inc, H2 2017

Migraine – Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017

Migraine – Pipeline by Trevena Inc, H2 2017

Migraine – Pipeline by Trigemina Inc, H2 2017

Migraine – Pipeline by TrioxBio Inc, H2 2017

Migraine – Pipeline by Vertex Pharmaceuticals Inc, H2 2017

Migraine – Pipeline by Xenon Pharmaceuticals Inc, H2 2017

Migraine – Pipeline by Zosano Pharma Corp, H2 2017

Migraine – Dormant Projects, H2 2017

Migraine – Dormant Projects, H2 2017 (Contd..1), H2 2017

Migraine – Dormant Projects, H2 2017 (Contd..2), H2 2017

Migraine – Dormant Projects, H2 2017 (Contd..3), H2 2017

Migraine – Dormant Projects, H2 2017 (Contd..4), H2 2017

Migraine – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Migraine, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports